Endomicroscopy and Gastric MALT-lymphoma
NCT01583699 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50
Last updated 2015-07-21
Summary
Extranodal marginal zone B-cell lymphoma (MZBL) of the mucosa associated lymphoid tissue (MALT-lymphoma) represents a distinct clinical entity and is the most common form of extranodal lymphoma, with a predilection for the stomach. About 90% of gastric MALT-lymphomas are associated with infection with Helicobacter pylori (HP) and eradication of the pathogen leads to regression of the tumor in a high percentage of patients at early tumour stages. Nevertheless, following complete remission after HP-eradication, the risk of relapse justifies lifelong follow-up examinations. Supported by recent findings at the investigators department, endoscopic controls should include a close examination of the small bowel, as relapses can involve different gastrointestinal sites. To continue the investigators diagnostic approach as well as to further improve the detection rate of MALT-lymphoma relapses, the investigators plan to introduce the novel confocal laser endomicroscope (CLE) into the diagnostic management of MALT-lymphoma patients. In the context of a prospective clinical pilot trial the investigators aim to establish MALT-lymphoma specific CLE-markers that can be used for the in vivo diagnosis of the disease. Comparing endomicroscopic findings, drawn from the stomach and small bowel of 50 MALT-lymphoma patients who will undergo staging or follow up endoscopies at the investigators department, to the histological evaluation of biopsy samples as present gold standard, the investigators want to determine whether CLE can provide reliable data for the accurate detection of MALT-lymphoma associated changes. Endomicroscopic aspects of patients with chronic gastritis, gastric adenocarcinoma and healthy subjects should serve as controls. In comparison to random biopsies which represent the current standard, the investigators aim to prove, whether endomicroscopy will find MALT-lymphoma lesions more accurately and thus help to spare patients unnecessary biopsies.
Conditions
- MALT-lymphoma
Interventions
- PROCEDURE
-
Confocal laser endomicroscopy
Endomicroscopy of the upper gastrointestinal tract to capture endomicroscopic pictures from the small bowel, stomach and esophagus.
- DEVICE
-
Confocal Laser Endomicroscope
Pentax EC-3870 CIFK with the ISC-1000 confocal endomicroscopy processor - Pentax, Tokyo, Japan and Optiscan Pty Ltd, Notting Hill, Victoria, Australia
Sponsors & Collaborators
-
Medical University of Vienna
lead OTHER
Principal Investigators
-
Werner Dolak, MD · Medical University of Vienna, Department of Internal Medicine III, Division of Gastroenterologie and Hepatologie
-
Andreas Puespoek, m · Medical University of Vienna, Department of Internal Medicine III, Division of Gastroenterology and Hepatology
-
Markus Raderer, MD · Medical University of Vienna, Department of Internal Medicine I, Division of Oncology
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-04-30
- Primary Completion
- 2014-03-31
- Completion
- 2014-03-31
Countries
- Austria
Study Locations
More Related Trials
-
Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma
NCT00897923 ·Status: COMPLETED
-
A Clinico-Pathological Study to Investigate the Possible Infective Causes of Non-Hodgkin Lymphoma of the Ocular Adnexae
NCT01010295 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma
NCT05868395 ·Status: RECRUITING ·Phase: PHASE2
-
Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma
NCT00656812 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma
NCT00944567 ·Status: COMPLETED
-
A Real-World Study on Extranodal Lymphoma
NCT06573099 ·Status: NOT_YET_RECRUITING
-
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma
NCT05846750 ·Status: RECRUITING ·Phase: PHASE2
-
Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma
NCT00387023 ·Status: COMPLETED ·Phase: NA
-
Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
NCT01996865 ·Status: COMPLETED ·Phase: PHASE3
-
MELT - MRI Evaluation of Lymphoma Treatment
NCT01459224 ·Status: COMPLETED
-
Lymphoma in the Orbit
NCT01302912 ·Status: UNKNOWN
-
Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma
NCT01599559 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Cohort Study for Gastric MALT Lymphoma
NCT06454149 ·Status: RECRUITING
-
Prospective Study of Possible Infectious Disease - Associated Antigen Drive in Previously Untreated Indolent Lymphoma
NCT00582270 ·Status: COMPLETED
-
The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP
NCT00440583 ·Status: COMPLETED ·Phase: PHASE2
-
Integrated Molecular and Clinical Profiling to Optimize Outcome Prediction in Splenic Marginal Zone Lymphoma
NCT02945319 ·Status: COMPLETED
-
MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
NCT06793189 ·Status: RECRUITING ·Phase: PHASE2
-
A Cohort Study in Newly Diagnosed MZL
NCT06449885 ·Status: RECRUITING
-
Whole-body Magnetic Resonance Imaging (MRI) for Staging Malignant Lymphomas
NCT00685997 ·Status: COMPLETED
-
Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma
NCT05700149 ·Status: RECRUITING
-
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma
NCT00453102 ·Status: COMPLETED ·Phase: PHASE2
-
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
NCT06651853 ·Status: RECRUITING ·Phase: PHASE2
-
Zanubrutinib in the Treatment of Recurrent Refractory Mantle Cell Lymphoma
NCT05486013 ·Status: RECRUITING
-
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
NCT07121946 ·Status: RECRUITING ·Phase: PHASE1
-
Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma
NCT07299331 ·Status: NOT_YET_RECRUITING ·Phase: NA